GlassScriptPhysician profile
Howard Roesen
NPI 1790721223
$1,128.73
in general payments reported to CMS, 2019-2025
18 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $53.43 · 2021: $168 · 2022: $199 · 2023: $148 · 2024: $113 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $181.54 | 2019-2025 | Clottriever Bold Catheter, Asnis, Dart-Fire |
| Convatec INC. | $179.99 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $145.35 | 2020-2025 | Nuzyra |
| Smith+Nephew, INC. | $100.43 | 2019-2023 | Collagenase Santyl, Regranex |
| Kerecis Limited | $84.49 | 2021-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Marigen |
| Bioventus LLC | $82.66 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Organogenesis INC. | $70.64 | 2020-2024 | |
| Heron Therapeutics, INC. | $52.57 | 2021-2022 | |
| Ibsa Pharma INC. | $45.94 | 2023-2024 | Tirosint, Tirosint, Licart |
| Nabriva Therapeutics, Plc | $33.96 | 2022 | |
| Boston Scientific Corporation | $30.33 | 2021-2024 | |
| Abbvie INC. | $22.55 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.55 | 2025 | Purified Cortrophin Gel |
| Dynasplint Systems INC. | $18.45 | 2025 | Dynasplint |
| Grt US Holding, INC. | $17.49 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $13.78 | 2019 | |
| Zyla Life Sciences, INC. | $13.57 | 2019 | |
| Fidia Pharma USA INC. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Roesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.